Figure 4.

Annualized progression rate of change in estimated glomerular filtration rate (mL/min/1.73 m²/year ± SD) for a male patient before ERT, and during treatment with agalsidase-alfa at 0.2 mg/kg every 2 weeks, followed by treatment with agalsidase-alfa at 0.4 mg/kg every 2 weeks. The progression slope was reduced in half with the higher dose of ERT. The urine protein excretion averaged 1.98 ± 0.03 (SD) g/24 h before ERT, 2.72 ± 0.52 (SD) g/24 h during ERT at 0.2 mg/kg every other week, and 1.17 ± 0.22 (SD) g/24 h during ERT at 0.4 mg/kg every other week along with enalapril at 5 mg 3 times per day. Adapted with permission Torra R, Algaba F, Ars E, et al 2008. Preservation of renal function in a patient with Fabry nephropathy on enzyme replacement therapy. Clin Nephrol, 69:445–9. Copyright © 2008 Dustri-Verlag.